CAR-T Therapy for Relapsed Lymphoma: Treatment Options in China
Published: Sep 28, 2026
Updated: Sep 28, 2026
Published: Sep 28, 2026
Updated: Sep 28, 2026
A lymphoma diagnosis can be challenging, especially when the disease returns after treatment or does not respond adequately to standard therapies. For some patients with relapsed or refractory lymphoma, CAR-T cell therapy has emerged as an advanced treatment option that uses the body's own immune cells to recognize and attack cancer cells.
China has become an important destination for patients exploring CAR-T therapy because of its growing expertise in cellular therapy, specialized cancer centers, clinical research programs, and availability of domestically developed CAR-T products.
For international patients, however, choosing the right hospital and understanding whether CAR-T therapy is appropriate can be complicated. MediGence can help international patients navigate the medical journey, while specialized healthcare providers such as GoBroadHealthcare Group (GHG) offer expertise in hematology, oncology, CAR-T therapy, and other advanced cancer treatments.
This guide explains CAR-T therapy for relapsed lymphoma, treatment options available in China, the treatment process, potential risks, research developments, and how MediGence can support patients exploring treatment in China.
Lymphoma is a cancer that develops in the lymphatic system, which is an important part of the immune system.
There are many types of lymphoma, but two major categories are:
Within non-Hodgkin lymphoma, several subtypes are classified as B-cell lymphomas. Some aggressive B-cell lymphomas can return after treatment or fail to respond to initial therapy.
Relapsed lymphoma means that the cancer has returned after a period in which treatment had successfully reduced or eliminated detectable disease.
Refractory lymphoma means that the cancer does not respond adequately to treatment or continues to progress despite therapy.
Patients with relapsed or refractory disease may require different treatment approaches, particularly when standard chemotherapy or other therapies have stopped working.
This is where CAR-T therapy may become an important treatment consideration for selected patients.
CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a form of personalized cancer treatment that uses the patient's own immune cells. In simple terms, the process works like this:
For many B-cell lymphomas, the target is a protein called CD19, which is commonly found on B cells. Unlike conventional chemotherapy, which directly affects rapidly dividing cells, CAR-T therapy is designed to train the patient's immune system to recognize and attack cancer cells.
Speak With a CAR-T Therapy Specialist in China Get your medical records reviewed by a qualified specialist to understand whether CAR-T therapy may be appropriate for your lymphoma, based on your diagnosis, previous treatments, and current health.
Treatment options can become more limited when lymphoma returns repeatedly or becomes resistant to conventional treatment.
CAR-T therapy has changed the treatment landscape for certain aggressive B-cell lymphomas. Clinical studies have demonstrated that some patients can achieve significant and durable responses after CAR-T treatment.
For example, studies of CAR-T products such as axicabtagene ciloleucel have demonstrated improved outcomes compared with conventional second-line treatment in selected patients with large B-cell lymphoma.
However, CAR-T therapy is not suitable for every patient. Eligibility depends on factors such as lymphoma subtype, previous treatments, disease status, overall health, organ function, and the specific CAR-T product being considered.
China has developed a rapidly expanding CAR-T ecosystem involving pharmaceutical companies, academic medical centers, research institutions, and specialized hospitals.
For relapsed or refractory large B-cell lymphoma, CD19-directed CAR-T therapies are among the important treatment approaches available in China.
Two commercially available CAR-T products frequently discussed in the Chinese lymphoma treatment landscape include:
Axicabtagene ciloleucel, commonly called axi-cel, is a CD19-directed CAR-T therapy used for certain B-cell lymphomas.
It has been studied extensively in aggressive large B-cell lymphoma, including patients whose disease has returned or failed to respond to previous treatment.
Relmacabtagene autoleucel, also known as relma-cel, is another CD19-directed CAR-T therapy developed and used in China for selected patients with relapsed or refractory B-cell lymphoma.
Chinese clinical research has reported meaningful response rates with relma-cel, including complete responses in a proportion of treated patients.
3. Clinical Trials and Next-Generation CAR-T
China is also conducting research into newer cellular therapies.
Researchers are investigating:
Clinical trials are experimental and may have specific eligibility criteria. Patients should discuss potential benefits and risks with a qualified oncology team before considering a clinical trial.
Research has shown that CAR-T therapy can produce substantial responses in some patients with relapsed or refractory lymphoma.
The ZUMA-7 study, for example, evaluated axicabtagene ciloleucel in patients with large B-cell lymphoma that was refractory to initial treatment or had relapsed within 12 months. The study found that patients receiving CAR-T therapy had better event-free survival than those receiving conventional second-line treatment.
Chinese research has also provided encouraging data.
The RELIANCE study evaluated relmacabtagene autoleucel in Chinese patients with relapsed or refractory large B-cell lymphoma. Follow-up results demonstrated durable responses in a proportion of patients.
Real-world Chinese studies have also evaluated CAR-T products in routine clinical settings. These studies are important because real-world patients may differ from the highly selected patients enrolled in clinical trials.
Overall, the research suggests that CAR-T therapy can provide meaningful and sometimes long-lasting disease control for selected patients. However, outcomes vary between individuals, and CAR-T therapy should not be described as a guaranteed cure.
The CAR-T treatment journey usually involves several stages.
The patient undergoes a detailed evaluation to determine whether CAR-T therapy may be appropriate.
Doctors may review:
The patient's T cells are collected from the blood through a procedure called leukapheresis.
The collected T cells are sent to a specialized manufacturing facility where they are genetically modified to express the CAR.
The modified cells are then expanded until enough cells are available for treatment.
Before receiving CAR-T cells, patients generally receive short-course chemotherapy.
This prepares the body for the infused CAR-T cells.
The engineered CAR-T cells are infused into the patient through an intravenous procedure.
Close monitoring is essential after the infusion because some side effects can occur during the early treatment period.
CAR-T therapy can be highly effective, but it can also cause significant side effects.
Two important complications are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
CRS occurs when the immune system becomes highly activated after CAR-T cells begin responding.
Symptoms may include:
Severe CRS can be life-threatening and requires immediate medical management.
Some patients may develop neurological complications, sometimes called ICANS.
Possible symptoms include:
Other potential complications include infections, reduced blood-cell counts, and depletion of normal B cells.
Because of these risks, CAR-T treatment should be administered in an experienced center with appropriate monitoring and emergency support.
China has invested significantly in cancer research and cellular therapy. Patients considering treatment in China may find:
The suitability of a particular hospital depends on the patient's diagnosis and treatment requirements rather than simply choosing a hospital based on reputation.
GoBroad Healthcare Group (GHG) is a research-oriented healthcare group in China with a focus on hematological diseases, oncology, clinical research, and advanced therapies including CAR-T treatment.
Its healthcare network includes specialized facilities in locations such as Beijing and Shanghai, with services extending into the Greater Bay Area.
For patients exploring CAR-T therapy, GoBroad Healthcare Group (GHG) is relevant because of its focus on hematology and oncology and its involvement in advanced cellular therapies.
GHG facilities include hospitals and specialized medical institutions such as:
Patients should confirm the current availability of a specific CAR-T product, treatment program, clinical trial, and international patient service directly with the treating institution before making travel arrangements.
For an international patient, receiving CAR-T therapy involves much more than selecting a treatment.
Patients may need help with:
MediGence can support international patients throughout these stages by helping coordinate access to specialists and healthcare institutions.
For patients considering CAR-T therapy in China, MediGence can help them explore appropriate treatment options and connect with specialized providers such as GoBroad Healthcare Group (GHG).
The role of MediGence is to simplify the international healthcare journey, while the medical team at GoBroad Healthcare Group (GHG) or another selected hospital is responsible for evaluating the patient and making clinical treatment decisions.
This distinction is important: CAR-T eligibility, product selection, treatment protocol, and medical outcomes must always be determined by qualified treating specialists.
Understand the potential cost of CAR-T treatment in China, including treatment-related expenses and other medical travel considerations. Trusted by 100000+ patients and leading medical experts. Explore CAR-T Therapy Costs in China
Several Chinese medical centers have experience in lymphoma treatment, CAR-T therapy, or cellular-therapy research.
Other academic and specialist centers across China also participate in CAR-T clinical research. The appropriate center depends on the patient's lymphoma subtype, previous treatment, eligibility, and the availability of the required CAR-T program.
Patients should avoid traveling before confirming that they may be eligible for the proposed treatment.
A medical-record review should ideally include:
Through MediGence, international patients can organize their medical information for specialist review and explore appropriate treatment centers.
If GoBroad Healthcare Group (GHG) is being considered, the patient's records can be reviewed by the relevant medical team to determine whether further evaluation or an in-person consultation is required.
CAR-T therapy can produce deep and durable responses in some patients, but it should not automatically be considered a guaranteed cure.
Some patients achieve complete remission, meaning that no detectable lymphoma is found using the tests performed. Others may experience partial responses or disease recurrence after treatment.
Doctors may recommend additional monitoring or other treatments depending on how the disease responds.
The long-term outcome depends on several factors, including lymphoma subtype, disease burden, previous treatments, patient health, CAR-T product, and individual response.
Yes. China has approved CAR-T therapies for certain blood cancers and has a growing network of hospitals and research centers providing CAR-T treatment and conducting clinical research.
Yes. China has an active CAR-T research environment, including studies investigating new CAR-T designs, targets, combinations, and next-generation cellular therapies. Clinical trials have specific eligibility requirements.
Important risks include cytokine release syndrome, neurological side effects, infections, low blood-cell counts, and reduced levels of normal B cells.
The overall process can take several weeks because cell collection, manufacturing, preparation, infusion, and monitoring are involved. The exact timeline varies by patient and treatment center.
Dr. Shagufta Parveen is a medical and scientific content writer with expertise in clinical pharmacology and pharmacotherapeutics. She holds a B.Pharm and Doctor of Pharmacy (Post-Baccalaureate) degree from Teerthanker Mahaveer University, Moradabad. During her clinical stint at BLK-Max Super Speciality Hospital and Indraprastha Apollo Hospital, she gained hands-on experience in the Clinical Pharmacology Department. Combining scientific knowledge with strong medical writing skills, Dr. Shagufta develops evidence-based healthcare content, treatment guides, and patient education resources. Her work focuses on simplifying complex medical concepts while maintaining scientific accuracy, helping readers better understand healthcare advancements and treatment options.
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practising as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute.
Delhi, India
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Active
.jpg)
